Eli Lilly and Company, Thermo Fisher Scientific, Johnson & Johnson, Pfizer, and Bristol-Myers Squibb are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity investments in companies that research, develop, manufacture, and market medications and other healthcare products. These stocks are influenced by factors such as clinical trial outcomes, regulatory approvals, patent expirations, and market demand, often providing significant growth potential but also carrying risks associated with scientific uncertainties and regulatory challenges. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of Eli Lilly and Company stock traded down $1.29 on Wednesday, hitting $826.25. 1,721,768 shares of the company's stock were exchanged, compared to its average volume of 3,423,234. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market capitalization of $783.43 billion, a PE ratio of 70.56, a PEG ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a 50-day simple moving average of $827.10 and a 200-day simple moving average of $818.99.
Read Our Latest Research Report on LLY
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE TMO traded up $2.77 during trading on Wednesday, hitting $437.50. The company had a trading volume of 2,240,410 shares, compared to its average volume of 1,728,295. The stock has a 50 day simple moving average of $493.38 and a 200 day simple moving average of $530.71. The firm has a market capitalization of $165.15 billion, a P/E ratio of 26.47, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific has a 12 month low of $409.85 and a 12 month high of $627.88.
Read Our Latest Research Report on TMO
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of NYSE JNJ traded down $2.70 during midday trading on Wednesday, reaching $155.05. The stock had a trading volume of 4,879,559 shares, compared to its average volume of 7,915,928. The company has a market capitalization of $373.65 billion, a price-to-earnings ratio of 23.32, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The stock has a 50-day moving average of $159.54 and a 200-day moving average of $154.95. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.
Read Our Latest Research Report on JNJ
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
PFE stock traded down $0.09 during trading on Wednesday, reaching $22.44. The company's stock had a trading volume of 33,342,401 shares, compared to its average volume of 40,428,323. The company's fifty day moving average is $24.75 and its 200-day moving average is $26.08. Pfizer has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a market capitalization of $127.27 billion, a P/E ratio of 15.92, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.
Read Our Latest Research Report on PFE
Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Shares of NYSE:BMY traded down $1.49 during trading on Wednesday, hitting $48.33. 14,868,739 shares of the company's stock were exchanged, compared to its average volume of 13,008,676. The business's 50-day simple moving average is $56.71 and its 200 day simple moving average is $56.59. The company has a market cap of $98.34 billion, a price-to-earnings ratio of -10.93, a PEG ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.
Read Our Latest Research Report on BMY
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
